Generate:Biomedicines announced the initiation of Phase 3 clinical studies for its lead TSLP (thymic stromal lymphopoietin) antibody, moving the AI-enabled discovery company’s lead program into late‑stage testing. The trials aim to provide registrational evidence across targeted indications. The move reflects a broader shift as AI-driven biotech ventures translate discovery-stage assets into clinical proof points and larger, costlier studies. Generate will focus resources on demonstrating efficacy and safety endpoints required for approval and commercial planning. Successful Phase 3 results would be a major validation for Generate’s platform and could accelerate investor interest in AI‑first biotechs transitioning to late‑stage development.